SCHEMBL373052

SCHEMBL373052

CC(=O)Nc1nc2ccccc2n1-c1nc(N2CCOCC2)cc(N2CCO[C@@H](C)[C@@H]2C)n1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ATR Q13535 11/20 0.56
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
HSD17B10 Q99714 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PIK3CB P42338 7/20 0.48
PIK3CA P42336 6/20 0.44
MTOR P42345 2/20 0.44
KCNH2 Q12809 2/20 0.44
PIK3CD O00329 4/20 0.41
PIK3CG P48736 4/20 0.41
PIK3R1 P27986 1/20 0.41
PDCD1 Q15116 4/20 0.41
CD274 Q9NZQ7 4/20 0.41
CHEK1 O14757 3/20 0.41
ATRIP Q8WXE1 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL373051 1.00 ATR (0.56) ATRCASP1CASP7HSD17B10L3MBTL1
SCHEMBL373050 1.00 ATR (0.56) ATRCASP1CASP7HSD17B10L3MBTL1
SCHEMBL373156 0.87 PIK3CB (0.52) ATRPIK3CBPIK3CAMTORKCNH2
SCHEMBL373155 0.87 PIK3CB (0.52) ATRPIK3CBPIK3CAMTORKCNH2
SCHEMBL373157 0.87 PIK3CB (0.52) ATRPIK3CBPIK3CAMTORKCNH2
SCHEMBL373393 0.83 ATR (0.58) ATRPIK3CBPIK3CAMTORPIK3CD
SCHEMBL373440 0.83 ATR (0.58) ATRPIK3CBPIK3CAMTORPIK3CD
SCHEMBL373441 0.83 ATR (0.58) ATRPIK3CBPIK3CAMTORPIK3CD
SCHEMBL373392 0.83 ATR (0.58) ATRPIK3CBPIK3CAMTORPIK3CD
SCHEMBL373391 0.83 ATR (0.58) ATRPIK3CBPIK3CAMTORPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071189-B2 Heterocyclic compound and antitumor agent containing the same as active ingredient ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2006-07-04 US claimed
EP-2409975-B1 Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound ZENYAKU KOGYO KK (JP) 2015-05-27 EP disclosed
US-8227463-B2 Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2012-07-24 US disclosed
EP-2409975-A1 Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-01-25 EP disclosed
US-20100249063-A1 AMORPHOUS BODY COMPOSED OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND PHARMACEUTICAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2010-09-30 US disclosed
EP-2218718-A1 AMORPHOUS FORM OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND MEDICINAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2010-08-18 EP disclosed
US-7307077-B2 Heterocyclic compound and antitumor agent containing the same as effective ingredient ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2007-12-11 US disclosed
EP-1389617-B1 HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT ZENYAKU KOGYO KK (JP) 2007-01-03 EP disclosed
US-20060247232-A1 Heterocyclic compound and antitumor agent containing the same as effective ingredient ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2006-11-02 US disclosed
US-7071189-B2 Heterocyclic compound and antitumor agent containing the same as active ingredient ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2006-07-04 US disclosed
US-20040116421-A1 Heterocyclic compound and antitumor agent containing the same as active ingredient OHARA PHARMACEUTICAL CO., LTD. (JP) 2004-06-17 US disclosed
EP-1389617-A1 HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2004-02-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249063-A1 AMORPHOUS BODY COMPOSED OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND PHARMACEUTICAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME SBDS, ABCG2, SSRP1 ATR 298/4885CASP1 2571/4885CASP7 2619/4885
US-20060247232-A1 Heterocyclic compound and antitumor agent containing the same as effective ingredient CBR3, HCCS, CBR1 ATR 1827/4885CASP1 917/4885CASP7 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.